elranatamab
pfizer
['elranatamab', 'multiplemyeloma', 'pfizer']
#pfizer presented 10.4 months follow-up data of elranatamab, a b-cell maturation antigen (bcma)-cd3-targeted bispecific antibody (bsab) in patients with advanced #multiplemyeloma #ash22 #ash2022 #bloodmatters #hematology #news #media #oncology #cancer
#iPharmaCenter is a #website which covers #pharmaceutical and #healthcare #news plus #blogs #diseases #drugs #healthcaresystems #globalhealth #pharma